Maze Therapeutics exchanges 2.78 million shares for pre-funded warrants with Frazier funds
Maze Therapeutics entered into an exchange agreement on October 15, 2026, with four Frazier Life Sciences funds. Maze exchanged 2,776,007 shares of common stock held by the funds for pre-funded warrants to buy the same number of shares, at an exercise price of $0.001 per share. The filing says the exchange does not change the total count of shares outstanding in the way a new issuance would, but it does create warrants that could later be converted into common stock.
Key points
- Exchange agreement dated October 15, 2026, with Frazier Life Sciences Public Fund, L.P. and affiliated Frazier funds
- 2,776,007 shares of common stock exchanged for pre-funded warrants with an exercise price of $0.001 per share
- Outstanding common stock was 53,931,889 shares as of October 16, 2026, after giving effect to the exchange
- Warrants cannot be exercised if the holder would own more than 9.99% of outstanding common stock, subject to certain exceptions
The filing
Written by AI on Nov 9, 2026, 11:45 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 16, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.